Affimed N.V. announced the appointment of Dr. Andreas Harstrick as Chief Medical Officer, starting in March 2020. In this role, he will oversee Affimed’s first-in-class innate cell engager clinical programs and lead the Company’s efforts to advance clinical-stage assets towards regulatory approvals. Dr. Harstrick brings to Affimed over 30 years of extensive experience in cancer drug development, including strategic leadership of three global phase 3 programs of new biological entities that culminated in global regulatory approvals, and multiple pivotal phase 3 studies. He has successfully designed clinical trials that have led to approval of antibody drugs, including Erbitux (cetuximab) and Portrazza (necitumumab), both which target the epidermal growth factor receptor (EGFR), and Cyramza (ramucirumab), a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist. Most recently, Dr. Harstrick was the Chief Medical Officer at Molecular Partners AG, where he oversaw clinical activities, including expansion of the clinical team, and was a member of the Management Board. At Molecular Partners, he successfully transitioned several preclinical programs to first-in-human studies. In addition, Dr. Harstrick has held several senior executive roles, including Senior Vice President Medical Sciences at ImClone Systems Inc., and following the acquisition of ImClone Systems by Eli Lilly and Company, he served as a member of the Lilly Oncology Program Review Board and Lilly Oncology Business Unit Development Committee. Prior to ImClone and Lilly, Dr. Harstrick was Senior Vice President Global Clinical Development Unit Oncology at Merck Serono. Dr. Harstrick, an oncologist by training, spent his medical career at the University Hospital and Cancer Center Hannover, Germany; the Roswell Park Cancer Institute, Buffalo NY; as well as the West German Cancer Center, Essen, Germany. He earned his MD at Medical School Hannover, Germany, and in 1999 he became Associate Professor for Internal Medicine, University of Essen, Germany.